Although quality and compliance auditing is not specifically required by drug GMPs, it has been an integral element of many pharmaceutical operations. The FDA has always expected self-audit programs and has criticized companies for failing to conduct such audits. This course will discuss some of the practical and proven techniques for conducting effective audits of various pharmaceutical operations, to identify the critical deficiencies associated with GMP compliance and product quality.
Audit principles covered in this training are based on the international recognized standard ISO 19011:2011. The content is tailor made for pharmaceutical and medical device organizations with strong focus on what to audit and how to verify compliance in the pharmaceutical and medical device industry. This training will give you the right tools regardless if you are going to audit the internal quality system against e.g. medical device regulations, ISO 13485 or GMP/QS requirements* or if you are going to audit suppliers/contract manufacturers.
* EU GMP Vol 4, 21 CFR210/211, EU GDP Guide, 21 CFR 820
You will also be prepared for the examination needed for personal certification as Auditor or Lead Auditor for Pharmaceuticals or Medical Devices. To receive and maintain the certification sufficient auditing experience is also required (read more about the personal certification at www.sbq.nu)
Attendees will gain practical knowledge in establishing an effective GMP compliance audit program and auditor training program. They will learn practical skills for conducting GMP compliance audits, and know what to look for when conducting audits of various pharmaceutical operations. They will be familiar with the audit tools that are available to them. Attendees will also have a chance to review and discuss current GMP compliance issues.
This course is intended for professionals who are responsible for GMP Compliance and Auditing, at both the beginner and advanced levels. Production and Quality professionals will benefit by learning the potential problem areas so that appropriate actions can be taken. Regulatory professionals who are responsible for FDA inspections and contact should also attend.
For your best experience are we using cookies on this website.